Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewOpicapone
Description: COMT inhibitor
Chemical Name: 5-[3-(2,5-Dichloro-4,6-dimethyl-1-oxido-3-pyridinyl)-1,2,4-oxadiazol-5-yl]-3-nitro-1,2-benzenediol
Purity: ≥98% (HPLC)
Biological Activity for Opicapone
Opicapone is a reversible catechol O-methyltransferase inhibitor (COMT) inhibitor (IC50 = 224 nM). Decreases the ATP content and mitochondrial membrane potential in cells (IC50 values are 98 μM and 181 μM respectively). When administered with L-DOPA (Cat. No. 3788) it attenuates Parkinson's-like symptoms in an MPTP-induced animal model.
Technical Data for Opicapone
| M. Wt | 413.17 |
| Formula | C15H10Cl2N4O6 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 923287-50-7 |
| PubChem ID | 135565903 |
| InChI Key | ASOADIZOVZTJSR-UHFFFAOYSA-N |
| Smiles | OC1=CC(C2=NC(C3=C(C(Cl)=C([N+]([O-])=C3Cl)C)C)=NO2)=CC([N+]([O-])=O)=C1O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Opicapone
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 41.32 | 100 |
Preparing Stock Solutions for Opicapone
The following data is based on the product molecular weight 413.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.42 mL | 12.1 mL | 24.2 mL |
| 5 mM | 0.48 mL | 2.42 mL | 4.84 mL |
| 10 mM | 0.24 mL | 1.21 mL | 2.42 mL |
| 50 mM | 0.05 mL | 0.24 mL | 0.48 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Opicapone
References for Opicapone
References are publications that support the biological activity of the product.
Ettcheto et al (2020) The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert Opin.Drug Discov. 15 993 PMID: 32450711
Bonifácio et al (2021) Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. Eur.J.Pharmacol. 892 173742 PMID: 33220276
If you know of a relevant reference for Opicapone, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Opicapone, Opicapone supplier, comt, inhibitors, catechol-O-methytransferases, mitochondrial, membrane, potential, ATP, LDOPA, levodopa, Parkinsons, Catechol, O-Methyltransferase, 7668, Tocris Bioscience
Citations for Opicapone
Citations are publications that use Tocris products.
Currently there are no citations for Opicapone. Do you know of a great paper that uses Opicapone from Tocris? Please let us know.
Reviews for Opicapone
There are currently no reviews for this product. Be the first to review Opicapone and earn rewards!
Have you used Opicapone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.